Telix Pharmaceuticals (TLX) Cash & Equivalents (2023 - 2025)

Telix Pharmaceuticals (TLX) has disclosed Cash & Equivalents for 3 consecutive years, with $141.9 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 69.46% to $141.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $141.9 million through Dec 2025, down 69.46% year-over-year, with the annual reading at $141.9 million for FY2025, 67.76% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $141.9 million at Telix Pharmaceuticals, down from $464.5 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $464.5 million in Q4 2024, with the low at $80.2 million in Q4 2023.
  • Average Cash & Equivalents over 3 years is $228.9 million, with a median of $141.9 million recorded in 2025.
  • The sharpest move saw Cash & Equivalents soared 479.03% in 2024, then plummeted 69.46% in 2025.
  • Over 3 years, Cash & Equivalents stood at $80.2 million in 2023, then skyrocketed by 479.03% to $464.5 million in 2024, then tumbled by 69.46% to $141.9 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $141.9 million, $464.5 million, and $80.2 million for Q4 2025, Q4 2024, and Q4 2023 respectively.